Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

NCT02839707 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02839707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02839707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 23, 2017
Completion date
May 11, 2027
Enrollment
444 (actual)
Sites
919

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube high grade serous adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian seromucinous carcinoma, primary peritoneal high grade serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent fallopian tube clear cell adenocarcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent fallopian tube undifferentiated carcinoma, recurrent ovarian carcinoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian undifferentiated carcinoma, recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent platinum-resistant primary peritoneal carcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal clear cell adenocarcinoma, recurrent primary peritoneal endometrioid adenocarcinoma, recurrent primary peritoneal undifferentiated carcinoma